Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Tabrecta
|
| gptkbp:CASNumber |
1029712-80-8
|
| gptkbp:chemicalFormula |
C24H25FN6O
|
| gptkbp:developer |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
Capmatinib
|
| gptkbp:indication |
MET exon 14 skipping mutation-positive NSCLC
|
| gptkbp:KEGGID |
D10941
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MET inhibitor
|
| gptkbp:molecularWeight |
432.5 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2364607 DB14894 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting fatigue dyspnea peripheral edema increased creatinine |
| gptkbp:target |
gptkb:MET_receptor
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|